| Factor | Score | Distribution | Value | Avg | Rank |
|---|---|---|---|---|---|
Valuation | 82 | 12.1x | 17.3x | Top tier | |
Growth | 97 | 70.5% | 7.1% | Top tier | |
Quality | 91 | 13.8% | 4.5% | Top tier | |
Safety | 72 | 1.5x | 2.6x | Top tier | |
Capital Return | 88 | 0.87% | 0.06% | Top tier | |
Momentum | 70 | -2.4% | -1.6% | Top tier | |
Sentiment | 86 | 6 | 3 | Top tier |
The floor: what the company is worth if growth stopped today
6% of today's price is what a buyer pays for growth that has not happened yet.
10-year US Treasury yield 4.96% as of 2026-10-22. Estimates computed from company data and analyst targets, not investment advice.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.
Haleon operates in consumer healthcare through a portfolio spanning oral health, pain relief, respiratory health, vitamins, minerals and supplements, and digestive health. The company relies on brands and products such as Sensodyne, Parodontax, Voltaren, Panadol, Advil, Centrum, Caltrate and Contac, and supports sales through innovation, distribution to retailers and hospitals, e-commerce, advertising and promotion, and engagement with dentists. Within the organic growth mix, oral health recorded growth of 6.2%, while the Clinical Repair, Centrum Age Defy, Panadol Dual Action and Voltaren 12-hour innovations supported performance across multiple markets.
In Q2 FY 2026 (ended 2026-06-30), revenue reached £5.6 billion, up 3.0% year over year from £5.5 billion in Q2 FY 2025. Net income was £767.6 million and diluted earnings per share were 0.17, while operating cash flow reached £902.6 million. Gross margin rose to 66.0% from 64.5%, and operating margin expanded to 23.8% from 22.0%, showing that profitability improved faster than revenue growth.
Geographically, progress came from improved execution and innovation in North America, high-single-digit growth in China and mid-teens growth in India, while Europe was more challenging, with Haleon growing by approximately 0.4% amid contraction in market categories. In North America, the company benefited from shelf resets, the launches of Clinical Repair and Centrum Age Defy, and e-commerce growth of more than 10% at twice the market growth rate. Increased use of GLP-1 drugs also supported U.S. demand for Haleon products related to digestive health and oral health through 2026-09-16.
Q2 FY2026
Last 12 months to 2026-06-30
When: FY 2026
Organic sales growth at 3%
When: Q4 FY 2026
Gross margin at 66.0%
Respiratory health growth at 0%
The value based on the industry multiple is $15 within a range of $10 to $29, pricing Haleon like its peers using earnings over the last 12 months and the median multiple of 17.6 for 19 companies. The median target of seven analysts is $10, while the average consensus target is $10.2; this method prices in expected growth and is inherently inclined toward optimism. The no-growth value is $9.28 at a discount rate of 8.8%, measuring what remains if current after-tax operating profit stays constant forever. Analyst targets and the no-growth value converge near $10, while the industry-multiple value is higher and has a wider range because it reflects peer pricing rather than assuming growth stops.
Figures in the text are as of 2026-09-27; the live price is shown at the top of the page.
In Q2 FY 2026 (ended 2026-06-30), revenue reached £5.6 billion and grew 3.0% year over year. Net income was £767.6 million, diluted earnings per share were 0.17, and operating cash flow was £902.6 million. Operating support came from shelf resets and innovation in North America, 6.2% growth in oral health, and improvement in China, India and Latin America.
Gross margin in Q2 FY 2026 (ended 2026-06-30) rose to 66.0% from 64.5% a year earlier, and operating margin rose to 23.8% from 22.0%. Management attributed the improvement to supply-chain productivity, including the standardization of packaging and formulations, reduced product complexity, and optimization of factories and the manufacturing network. At the same time, the company increased advertising and promotion spending by 3.2% in the first half and allocated 60% of spending to digital media.
Automated analysis for informational purposes only — not investment advice.
When: H2 FY 2026
Emerging markets growth at 8%
On 2026-09-16, Haleon's sales growth in the United States was linked to increased demand for products addressing the side effects of GLP-1 drugs such as Ozempic and Wegovy. The benefit was concentrated in digestive health and oral health solutions used by consumers to manage associated symptoms. Haleon also launched a version of Centrum specifically for GLP-1 users as part of its efforts to expand its vitamins, minerals and supplements portfolio.
Management maintained its FY 2026 organic sales growth guidance at 3% to 5%, following annual revenue growth of 3.0% in Q2 FY 2026 (ended 2026-06-30). The obstacles are weakness in Europe, market declines in Dubai and Pakistan, and the respiratory health impact that reduced organic growth by approximately 1.5 percentage points in the second quarter. The second half requires improvement in North America and emerging markets and a return to growth in cough, cold and flu during Q4 FY 2026.